Celsion Corp. (NASDAQ:CLSN) has been given a $4.00 target price by research analysts at Maxim Group in a research note issued to investors on Tuesday. The brokerage currently has a a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 250.88% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Celsion Corp. in a report on Tuesday, July 12th.

Shares of Celsion Corp. (NASDAQ:CLSN) traded down 2.56% during mid-day trading on Tuesday, hitting $1.14. 74,734 shares of the stock traded hands. The firm has a 50 day moving average of $1.22 and a 200 day moving average of $1.34. Celsion Corp. has a 12 month low of $1.04 and a 12 month high of $2.31. The company’s market cap is $29.42 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/maxim-group-reiterates-4-00-price-target-for-celsion-corp-clsn.html

Celsion Corp. (NASDAQ:CLSN) last issued its earnings results on Monday, August 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative net margin of 3,966.14% and a negative return on equity of 103.07%. Equities analysts anticipate that Celsion Corp. will post ($0.83) EPS for the current fiscal year.

A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC raised its position in Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned about 6.48% of Celsion Corp. worth $1,930,000 as of its most recent SEC filing. 15.19% of the stock is owned by institutional investors and hedge funds.

About Celsion Corp.

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

5 Day Chart for NASDAQ:CLSN

Receive News & Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related companies with MarketBeat.com's FREE daily email newsletter.